vimarsana.com
Home
Live Updates
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million : comparemela.com
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumorPivotal Phase 3 clinical study of vorasidenib demonstrated unprecedented...
Related Keywords
United States ,
Johnson Imbruvica ,
Pablo Legorreta ,
Roche Evrysdi ,
Johnson Tremfya ,
Novarti Promacta ,
Nasdaq ,
Fenwick West ,
Exchange Commission ,
Goodwin Procter ,
Drug Administration ,
Agios Pharmaceutical ,
Chief Executive Officer ,
Royalty Pharma ,
Breakthrough Therapy Designation ,
Prescription Drug User Fee Act ,
Pharma Investor Relations ,
comparemela.com © 2020. All Rights Reserved.